Cambridge start-up Lucida Medical gains CE mark for AI software that aids accurate prostate cancer diagnosis

Published by
Cambridge Independent

New AI-based software that can improve the process of diagnosing prostate cancer has received a CE mark. Cambridge start-up Lucida Medical is celebrating the progress of its Prostate Intelligence (Pi) technology, which can now be used across the UK or European healthcare systems. The company intends to make it commercially available in the UK and EU in the first quarter of 2024. Prostate cancer is the most common cancer in men, claiming 375,000 lives annually, and is notoriously difficult to diagnose. MRI scans are the preferred imaging technique for diagnosing prostate cancer, along with a nu…

Read More

See also  Former Google engineers presented robot vacuum cleaner completely different from others - Photo

Leave a Reply